United States Biotechnology & Medical Research

Vigil Neuroscience Inc (VIGL)

Track

Ticker: VIGL Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Vigil Neuroscience Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 19 Dec 2024
Value US$2,380,085.43 | Price 162.33 | Shares 34,506 (+34.2%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-12-19 2024-12-19 B Purchase
3.1
Magovcevic-Liebisch Ivana

President and CEO

Executive Director
34,506 +34.2%
162.33
US$2,380,085 		34,506 +34.2% 162.33 US$2,380,085
2024-12-19 2024-12-19 B Purchase
2.5
Budd Haeberlein Samantha L.
Non-Executive Director
97,297 -1.7%
379.30
US$2,572,640 		97,297 -1.7% 379.30 US$2,572,640
2024-12-18 2024-12-18 B Purchase
3.1
Magovcevic-Liebisch Ivana

President and CEO

Executive Director
31,682 -2.2%
496.51
US$556,091 		31,682 -2.2% 496.51 US$556,091
2024-12-05 2024-12-05 B Purchase
3.1
Magovcevic-Liebisch Ivana

President and CEO

Executive Director
5,000 +2.4%
2.34
US$11,700 		5,000 +2.4% 2.34 US$11,700
2024-09-19 2024-09-19 PrS Proposed sale
2.4
Verni Christopher

FORMER OFFICER

Officer
40,000
3.63
US$145,000 		40,000 3.63 US$145,000
2023-11-20 2023-11-20 B Purchase
3.1
Magovcevic-Liebisch Ivana

President and CEO

Executive Director
4,000 +2.0%
3.75
US$15,000 		4,000 +2.0% 3.75 US$15,000
2022-11-22 2022-11-18 PlS Planned sale
2.7
Papapetropoulos Spyros

Chief Medical Officer

Officer
300 -7.0%
14.00
US$4,200 		300 -7.0% 14.00 US$4,200
2022-05-17 2022-05-17 B Purchase
3.7
Thorp Clay
Non-Executive Director
14,893 +1.0%
2.97
US$44,189 		14,893 +1.0% 2.97 US$44,189
2022-05-17 2022-05-16 B Purchase
3.7
Thorp Clay
Non-Executive Director
21,802 +1.4%
2.76
US$60,221 		21,802 +1.4% 2.76 US$60,221
2022-05-06 2022-05-05 B Purchase
2.4
Thackaberry Evan

SVP, Head of Early Development

Officer
1,500 +inf%
4.00
US$6,000 		1,500 +inf% 4.00 US$6,000
2022-05-04 2022-05-03 B Purchase
2.4
Verni Christopher

General Counsel

Officer
4,000 +inf%
3.77
US$15,074 		4,000 +inf% 3.77 US$15,074
2022-05-04 2022-05-03 B Purchase
3.1
Magovcevic-Liebisch Ivana

President and CEO

Executive Director
1,000 +0.5%
3.94
US$3,940 		1,000 +0.5% 3.94 US$3,940
2022-05-04 2022-05-03 B Purchase
3.0
Ziolkowski Jennifer Lynn

Chief Financial Officer

Officer
4,000 +inf%
3.77
US$15,098 		4,000 +inf% 3.77 US$15,098
2022-05-04 2022-05-03 B Purchase
2.7
Papapetropoulos Spyros

Chief Medical Officer

Officer
4,000 +inf%
3.40
US$13,591 		4,000 +inf% 3.40 US$13,591
2022-05-04 2022-05-02 B Purchase
3.1
Magovcevic-Liebisch Ivana

President and CEO

Executive Director
4,000 +2.0%
3.61
US$14,439 		4,000 +2.0% 3.61 US$14,439
2022-03-28 2022-03-28 B Purchase
3.7
Thorp Clay
Non-Executive Director
3,000 +inf%
7.20
US$21,604 		3,000 +inf% 7.20 US$21,604
2022-01-11 2022-01-11 B Purchase
3.4
Booth Bruce
Non-Executive Director
535,000 +12.5%
14.00
US$7,490,000 		535,000 +12.5% 14.00 US$7,490,000
2022-01-11 2022-01-11 B Purchase
Northpond Ventures GP, LLC
Large shareholder
355,000 +34.5%
14.00
US$4,970,000 		355,000 +34.5% 14.00 US$4,970,000
2022-01-11 2022-01-11 B Purchase
Vida Ventures GP III, L.L.C.
Large shareholder
3,852 +50.1%
14.00
US$53,928 		3,852 +50.1% 14.00 US$53,928
2022-01-11 2022-01-11 B Purchase
Vida Ventures GP III, L.L.C.
Large shareholder
1,671,148 +50.1%
14.00
US$23,396,072 		1,671,148 +50.1% 14.00 US$23,396,072
2022-01-11 2022-01-11 B Purchase
Vitorovic Stefan
Non-Executive Director
3,852 +50.1%
14.00
US$53,928 		3,852 +50.1% 14.00 US$53,928
2022-01-11 2022-01-11 B Purchase
Vitorovic Stefan
Non-Executive Director
1,671,148 +50.1%
14.00
US$23,396,072 		1,671,148 +50.1% 14.00 US$23,396,072
2022-01-11 2022-01-11 B Purchase
Atlas Venture Fund XII, L.P.
Large shareholder
535,000 +12.5%
14.00
US$7,490,000 		535,000 +12.5% 14.00 US$7,490,000
2022-01-11 2022-01-11 B Purchase
3.7
Thorp Clay
Non-Executive Director
265,000 +21.1%
14.00
US$3,710,000 		265,000 +21.1% 14.00 US$3,710,000
Explore more

More insider trading research around Vigil Neuroscience Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America